This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Dr. Reddy's Semaglutide weight-loss drug launch in Canada faces delays due to regulatory compliance issues, impacting share ...

Novo Nordisk India and Emcure Pharma are partnering to introduce Poviztra, a weight-loss medication based on semaglutide, in India. This collaboration aims to enhance accessibility and distribution of ...

As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...